To: All persons or entities who purchased or otherwise acquired securities of Edge Therapeutics, Inc. (“Edge Therapeutics”) (NASDAQ: EDGE) between December 29, 2017 and March 27, 2018. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of New Jersey. To get more information on the Edge Therapeutics class action (EDGE class action lawsuit), go to: http://www.zlk.com/pslra-d/edge-therapeutics-inc or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) Edge Therapeutics lead product candidate EG-1962 would likely fail a futility analysis in connection with the NEWTON 2 study; and (2) as a result of the foregoing, the Company’s financial statements and Defendants’ statements about Edge’s business, operations, and prospects, were materially false and misleading at all relevant times.

If you suffered a loss in Edge Therapeutics you have until June 22, 2018 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

For more information on the Edge Therapeutics class action lawsuit (EDGE class action lawsuit), contact Levi & Korsinsky. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.